Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 8/20 | 0.59 |
| ▸ | DRD2 | P14416 | 5/20 | 0.59 |
| ▸ | DRD3 | P35462 | 4/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
| ▸ | HTR7 | P34969 | 1/20 | 0.57 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17871853 | 0.84 | POLB (0.55) | DRD4DRD2DRD3SIGMAR1HTR7 | |
| SCHEMBL3088832 | 0.82 | DRD4 (0.54) | DRD4DRD2DRD3HTR7MAPT | |
| SCHEMBL5356203 | 0.80 | DRD4 (0.55) | DRD4DRD2DRD3HTR7 | |
| SCHEMBL6864941 | 0.80 | DRD4 (0.81) | DRD4DRD2DRD3SIGMAR1HTR7 | |
| SCHEMBL20140902 | 0.79 | HTR7 (0.48) | DRD4DRD2DRD3HTR7 | |
| SCHEMBL20140770 | 0.79 | ALDH1A1 (0.51) | DRD4DRD2DRD3HTR7NPSR1 | |
| Water SCHEMBL8695926 | 0.78 | SIGMAR1 (0.95) | DRD4SIGMAR1 | |
| SCHEMBL20140731 | 0.78 | DRD4 (0.54) | DRD4DRD2DRD3HTR7 | |
| SCHEMBL20139955 | 0.78 | KDM4E (0.52) | DRD4DRD2DRD3HTR7CHRM4 | |
| SCHEMBL5393900 | 0.78 | LMNA (0.67) | MAPTTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115867-A1 | NEW CLASS OF HISTONE DEACETYLASE INHIBITORS | DAC S.R.L. (IT) | 2012-05-10 | — | — | US | disclosed |
| EP-2197854-B1 | A NEW CLASS OF HISTONE DEACETYLASE INHIBITORS | DAC SRL (IT) | 2011-08-10 | — | — | EP | disclosed |
| US-20100305123-A1 | CLASS OF HISTONE DEACETYLASE INHIBITORS | DAC S.R.L. (IT) | 2010-12-02 | — | — | US | disclosed |
| EP-2197854-A1 | A NEW CLASS OF HISTONE DEACETYLASE INHIBITORS | DAC S.r.l. (IT) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009027395-A1 | A NEW CLASS OF HISTONE DEACETYLASE INHIBITORS | DAC S.R.L. (IT) | 2009-03-05 | — | — | WO | disclosed |
| EP-1205473-A1 | VESAMICOL PIPERAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME | DAIICHI RADIOISOTOPE LABORATORIES, LTD. (JP) | 2002-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115867-A1 | NEW CLASS OF HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC5, HDAC1 | DRD4 966/4885DRD2 791/4885DRD3 543/4885 |
| US-20100305123-A1 | CLASS OF HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC5 | DRD4 1027/4885DRD2 794/4885DRD3 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.